Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
暂无分享,去创建一个
Christine Y. Lu | B. Kiely | N. Houssami | R. Ward | S. Pearson | S. Lord | B. Daniels
[1] L. Pusztai,et al. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. , 2018, The oncologist.
[2] Christine Y. Lu,et al. Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016). , 2018, Breast.
[3] Christine Y. Lu,et al. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014) , 2017, British Journal of Cancer.
[4] S. Rodenhuis,et al. Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle , 2017 .
[5] A. Tutt,et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Christine Y. Lu,et al. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort , 2017, BMJ Open.
[7] A. Tutt,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.
[8] G. Hortobagyi,et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.
[9] W. Lipworth,et al. Access to new cancer medicines in Australia: dispelling the myths and informing a public debate , 2016, Journal of Pharmaceutical Policy and Practice.
[10] S. Merajver,et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.
[11] I. Smith,et al. Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. , 2015, Breast.
[12] F. André,et al. Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA. , 2015, Breast.
[13] Martin Schumacher,et al. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time , 2015, Clinical Cancer Research.
[14] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[15] E. Espinosa,et al. The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy , 2014, PloS one.
[16] M. Stockler,et al. Rising cost of anticancer drugs in Australia , 2014, Internal medicine journal.
[17] H. Rugo,et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER , 2014, British Journal of Cancer.
[18] F. Jänicke,et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry , 2014, BMC Cancer.
[19] Erin M. Olson,et al. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. , 2013, Clinical breast cancer.
[20] F. Claret,et al. Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..
[21] G. Hortobagyi,et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Ward,et al. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.